ReviewFrontiers in cell and developmental biology2026
Involvement of the pyroptosis-HMGB1 axis in systemic diseases.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyroptosis is a lytic form of regulated cell death driven by inflammasome activation and gasdermin-mediated membrane rupture, characterized by robust inflammatory amplification. High-mobility group box 1 (HMGB1), a multifunctional nuclear protein and damage-associated molecular pattern, has emerged as a central regulator within pyroptosis-associated pathologies. Acting both as a downstream alarmin released during pyroptotic cell death and as an upstream licensing factor for inflammasome activation and innate immune signaling, HMGB1 establishes a context-dependent feedforward loop that shapes tissue injury and immune responses. In infectious and inflammatory disorders, excessive HMGB1 release exacerbates immune dysregulation and organ damage, whereas in selected tumor settings, pyroptosis-associated HMGB1 contributes to immunogenic cell death and antitumor immunity. This review systematically summarizes the molecular mechanisms underlying HMGB1-regulated pyroptosis, including canonical and noncanonical inflammasome pathways, gasdermin execution, and crosstalk with other regulated cell death programs. We further integrate evidence implicating the pyroptosis-HMGB1 axis across systemic diseases involving the nervous, respiratory, digestive, circulatory, urinary, locomotor, endocrine, reproductive, and immune systems. Finally, we discuss emerging therapeutic strategies targeting this axis, highlighting opportunities and challenges for disease-specific and precision interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.